Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Indapamide is a thiazide diuretic used to treat hypertension as well as edema due to congestive heart failure. The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension.
- Mechanism
- Curator reviewed · 8 references
Indapamide acts on the nephron, specifically at the proximal segment of the distal convoluted tubule where it inhibits the Na+/Cl- cotransporter, leading to reduced sodium reabsorption. As a result, sodium and water are retained in the lumen of the nephron for urinary excretion. The effects that follow include reduced plasma volume, reduced venous return, lower cardiac output, and ultimately decreased blood pressure.
Interestingly, it is likely that thiazide-like diuretics such as indapamide have additional blood pressure lowering mechanisms that are unrelated to diuresis. This is exemplified by the observation that the antihypertensive effects of thiazides are sustained 4-6 weeks after initiation of therapy, despite recovering plasma and extracellular fluid volumes.
Some studies have suggested that indapamide may decrease responsiveness to pressor agents while others have suggested it can decrease peripheral resistance. Although it is clear that diuresis contributes to the antihypertensive effects of indapamide, further studies are needed to investigate the medication’s ability to decrease peripheral vascular resistance and relax vascular smooth muscle.
- Primary indication
- Indapamide is a diuretic indicated for use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension.Curator reviewed · 5 structured indications
- Formula / weight
- C16H16ClN3O3S · 365.835 g/mol (avg)
- First approval
- Canada, 1999 · United States, 1983
- Also known as
- Metindamide
- Code names
- BR1015-2 · RHC 2555 · S 1520 · SE 1520 · USV 2555
- Brand names
- Coversyl
- Widaplik
Resolves to
NDDAHWYSQHTHNT-UHFFFAOYSA-NSMILESCC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=OWhat you can answer from here — as of September 16, 2026
Which drugs share a target with Indapamide, and which of those have an active Phase 3 trial?